These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 16509026)

  • 1. Pharmacoeconomic modeling of nesiritide versus dobutamine for decompensated heart failure.
    Gerhard T; Zineh I; Winterstein AG; Hartzema AG
    Pharmacotherapy; 2006 Jan; 26(1):34-43. PubMed ID: 16509026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic implications of nesiritide versus dobutamine in the treatment of patients with acutely decompensated congestive heart failure.
    de Lissovoy G; Stier DM; Ciesla G; Munger M; Burger AJ
    Am J Cardiol; 2003 Sep; 92(5):631-3. PubMed ID: 12943895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes associated with vasoactive therapy in patients with acute decompensated heart failure.
    Arnold LM; Crouch MA; Carroll NV; Oinonen MJ
    Pharmacotherapy; 2006 Aug; 26(8):1078-85. PubMed ID: 16863484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dobutamine Therapy is Associated with Worse Clinical Outcomes Compared with Nesiritide Therapy for Acute Decompensated Heart Failure: A Systematic Review and Meta-Analysis.
    Wang XC; Zhu DM; Shan YX
    Am J Cardiovasc Drugs; 2015 Dec; 15(6):429-37. PubMed ID: 26123415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure.
    Silver MA; Horton DP; Ghali JK; Elkayam U
    J Am Coll Cardiol; 2002 Mar; 39(5):798-803. PubMed ID: 11869844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased cost effectiveness with nesiritide vs. milrinone or dobutamine in the treatment of acute decompensated heart failure.
    Scroggins N; Edwards M; Delgado R
    Congest Heart Fail; 2005; 11(6):311-4. PubMed ID: 16330906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of death with nesiritide.
    Burger AJ
    JAMA; 2005 Aug; 294(8):897; author reply 898. PubMed ID: 16118377
    [No Abstract]   [Full Text] [Related]  

  • 8. Nesiritide Therapy Is Associated With Better Clinical Outcomes Than Dobutamine Therapy in Heart Failure.
    Kong LG; Wang CL; Zhao D; Wang B
    Am J Ther; 2017; 24(2):e181-e188. PubMed ID: 26164026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of nesiritide (human b-type natriuretic peptide) and dobutamine on heart rate variability in decompensated heart failure.
    Aronson D; Burger AJ
    Am Heart J; 2004 Nov; 148(5):e16. PubMed ID: 15523294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study.
    Burger AJ; Horton DP; LeJemtel T; Ghali JK; Torre G; Dennish G; Koren M; Dinerman J; Silver M; Cheng ML; Elkayam U;
    Am Heart J; 2002 Dec; 144(6):1102-8. PubMed ID: 12486437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials.
    Sackner-Bernstein JD; Kowalski M; Fox M; Aaronson K
    JAMA; 2005 Apr; 293(15):1900-5. PubMed ID: 15840865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of recombinant human B-type natriuretic peptide (nesiritide) in the management of acute decompensated heart failure.
    Strain WD
    Int J Clin Pract; 2004 Nov; 58(11):1081-7. PubMed ID: 15605677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous levosimendan treatment is cost-effective compared with dobutamine in severe low-output heart failure: an analysis based on the international LIDO trial.
    Cleland JG; Takala A; Apajasalo M; Zethraeus N; Kobelt G
    Eur J Heart Fail; 2003 Jan; 5(1):101-8. PubMed ID: 12559222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The ASCEND-HF trial: an acute study of clinical effectiveness of nesiritide and decompensated heart failure.
    Dandamudi S; Chen HH
    Expert Rev Cardiovasc Ther; 2012 May; 10(5):557-63. PubMed ID: 22651831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The costs of treating acute heart failure: an economic analysis of the SURVIVE trial.
    de Lissovoy G; Fraeman K; Salon J; Chay Woodward T; Sterz R
    J Med Econ; 2008; 11(3):415-29. PubMed ID: 19450096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of patients hospitalized for acute decompensated heart failure: does nesiritide make a difference?
    Carroll RJ; Mulla ZD; Hauck LD; Westbrook A
    BMC Cardiovasc Disord; 2007 Nov; 7():37. PubMed ID: 18039381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale and design of the pilot randomized study of nesiritide versus dobutamine in heart failure (PRESERVD-HF).
    Gheorghiade M; Gattis WA; Adams KF; Jaffe AS; O'Connor CM; ;
    Am Heart J; 2003 Feb; 145(2 Suppl):S55-7. PubMed ID: 12594453
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison of the occurrence of ventricular arrhythmias in patients with acutely decompensated congestive heart failure receiving dobutamine versus nesiritide therapy.
    Burger AJ; Elkayam U; Neibaur MT; Haught H; Ghali J; Horton DP; Aronson D
    Am J Cardiol; 2001 Jul; 88(1):35-9. PubMed ID: 11423055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nesiritide: a review of its use in acute decompensated heart failure.
    Keating GM; Goa KL
    Drugs; 2003; 63(1):47-70. PubMed ID: 12487622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous nesiritide in acute heart failure.
    Knox MA; Dancy T; Mook W; Pschirer JJ
    Am J Ther; 2005; 12(3):233-7. PubMed ID: 15891267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.